de Wit R, de Bono J, Sternberg CN, et al. - Experts randomized 255 individuals with metastatic castration-resistant prostate cancer and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide), in a 1:1 ratio, who had formerly received docetaxel and an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel or the other androgen-signaling–targeted inhibitor in order to determine the efficiency and safety of cabazitaxel, in comparison with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide). In 56.3% of individuals who were receiving cabazitaxel and in 52.4% of those who were receiving an androgen-signaling–targeted inhibitor, the occurrence of adverse events of grade 3 or higher was noted. No new safety signals were recognized. In individuals with metastatic castration-resistant prostate cancer who had been formerly treated with docetaxel and the alternative androgen-signaling–targeted agent (abiraterone or enzalutamide), in comparison with the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), cabazitaxel significantly enhanced a number of clinical outcomes.